Stablor
Commercial- Indications
- Pre-diabetes, Obesity, Abdominal obesity
Company intelligence / Profile preview
LNC specializes in developing patented medical nutrition products targeting major metabolic diseases such as diabetes and cardiovascular disease. Their lead product Stablor® is designed to reduce visceral fat while preserving lean mass. Clinical studies have been conducted internationally; however, some health claims were not approved by EFSA due to insufficient statistical significance or study design limitations. The company aims to license its products to pharmaceutical partners after successful clinical validation.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Laboratoires Nutrition et Cardiometabolisme.